Network with fellow biopharma, academic, and government professionals and learn about the rapidly-growing field of cell and gene therapy. Featuring keynote speaker Peter Marks, M.D., Ph.D., Director of the U.S. [….]
Institute for Bioscience and Biotechnology Research Receives $16.8 M Investment from the National Institute of Standards and Technology
The Institute for Bioscience and Biotechnology Research (IBBR) announces a newly funded five-year cooperative agreement with the National Institute of Standards and Technology (NIST) headed by the Co-Directors of IBBR, Dr. David J. Weber (PI) and Dr. John Marino (NIST). This award provides more than $3.3 million each year to support groundbreaking research, including technology and standards development that will impact vaccine and therapeutic discovery and development, and to improve access to life-saving treatments for addressing other crucial health challenges.
USP, NIST & NIIMBL Researchers Collaborate to Improve Measurement of Viral Vectors Used in Cutting-Edge Gene Therapy
The United States Pharmacopeia (USP), the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) and The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) have announced a research collaboration to assess analytical methods and develop standards for adeno-associated virus (AAV), an important mechanism for delivering gene therapies.